Company intelligence / Profile preview

Megalabs

Ownership: Private
Employees: ~7300
Development stage: Other

Overview

Megalabs is a leading Latin American pharmaceutical company with a broad portfolio of over 1,800 products across all major therapeutic areas. The company develops and manufactures both small molecules and biologics, including biosimilars. Its most advanced known clinical program is an epoetin alfa biosimilar in Phase 3 trials for anemia associated with chronic kidney disease[6]. The group has made recent strategic acquisitions to expand its consumer health and skincare offerings[2].

Therapeutic areas: Nephrology
Modalities: Small moleculeBiosimilarColony-stimulating factors (biologic)
Industry: Pharma

Drug pipeline

1 asset

epoetin alfa Megalabs

Unknown

Partnerships

Logmore (pharmaceutical logistics QA technology partner)

Beyond the preview

Go deeper on Megalabs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Megalabs.

Explore the full profile